BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19220049)

  • 1. Ligand-based neutral ruthenium(II) arene complex: selective anticancer action.
    Wu CH; Wu DH; Liu X; Guoyiqibayi G; Guo DD; Lv G; Wang XM; Yan H; Jiang H; Lu ZH
    Inorg Chem; 2009 Mar; 48(6):2352-4. PubMed ID: 19220049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arene ruthenium complexes as anticancer agents.
    Süss-Fink G
    Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
    Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
    Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
    Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
    Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, structure, DNA-binding properties, and cytotoxicity of ruthenium(II) polypyridyl complexes.
    Liu YJ; Zeng CH; Yao JH; Wu FH; He LX; Huang HL
    Chem Biodivers; 2010 Jul; 7(7):1770-83. PubMed ID: 20658665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
    Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
    Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
    Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
    Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex.
    Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
    J Med Chem; 2014 Apr; 57(8):3546-58. PubMed ID: 24669938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands.
    Kurzwernhart A; Kandioller W; Bächler S; Bartel C; Martic S; Buczkowska M; Mühlgassner G; Jakupec MA; Kraatz HB; Bednarski PJ; Arion VB; Marko D; Keppler BK; Hartinger CG
    J Med Chem; 2012 Dec; 55(23):10512-22. PubMed ID: 23134291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs.
    Hotze AC; Kariuki BM; Hannon MJ
    Angew Chem Int Ed Engl; 2006 Jul; 45(29):4839-42. PubMed ID: 16802394
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis, characterization, and antitumor activity of water-soluble (arene)ruthenium(II) derivatives of 1,3-dimethyl-4-acylpyrazolon-5-ato ligands. First example of Ru(arene)(ligand) antitumor species involving simultaneous Ru-N7(guanine) bonding and ligand intercalation to DNA.
    Caruso F; Monti E; Matthews J; Rossi M; Gariboldi MB; Pettinari C; Pettinari R; Marchetti F
    Inorg Chem; 2014 Apr; 53(7):3668-77. PubMed ID: 24611608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.